9:40AM Phase Forward agrees to acquire Covance's interactive voice and web response services business (PFWD) 12.59 +0.13 : Co announces that it has signed an agreement to purchase the Interactive Voice & Web Response Services (IVRS/IWRS) business of Covance (CVD) for $10 million in cash. As part of this transaction, Phase Forward and Covance have also agreed to enter into a multi-year marketing agreement to provide Phase Forward's market leading InForm electronic data capture solution and Clarix interactive response technology solution to Covance clients.

9:31AM Pfizer announces new Phase 1 Data from two novel compounds for Alzheimer's disease (PFE) 14.97 +0.06 : Co announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer's disease. Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation (MDVN) is in Phase 3 development. Results showed PF-04360365 was well-tolerated over this dose range. Routine safety lab values were unremarkable and there were no safety signals from brain Magnetic Resonance Imaging, electrocardiograms, cognitive scales or physical/neurological examinations.1 While the one-year observation period is still ongoing, the most common adverse events observed to date were upper respiratory tract infection, headache, back pain and diarrhea, and all were mild to moderate in severity.

9:31AM ShoreTel announces an agreement with IBM (IBM) (SHOR) 8.14 +0.03 : Co announces an agreement with IBM (IBM) to deliver a unique unified communications and collaboration offering that combines a small business appliance, presence awareness, instant messaging and VoIP telephony.

9:18AM Natural gas drops sharply from session highs, at $3.527, back to the flat line; currently up 0.8 cents to $3.427 :  

9:09AM MTR Gaming announces proposed offering of $250 mln in senior secured notes due 2014 (MNTG) 3.58 :  

9:08AM AMR Corp reports narrower than expected loss, reports revs in-line (AMR) 4.18 : Reports Q2 (Jun) loss of $1.14 per share, $0.14 better than the First Call consensus of ($1.28); revenues fell 20.9% year/year to $4.89 bln vs the $4.9 bln consensus. Results exclude a $70 mln in non-recurring charges related to the sale of certain aircraft and the grounding of leased Airbus A300 aircraft prior to lease expiration. AMR expects its full-year mainline capacity to decrease by approximately 7.5% in 2009 compared to 2008, with a reduction of domestic capacity of approximately 9 percent and a reduction of international capacity of more than 4% compared to 2008 levels. On a consolidated basis, AMR expects full-year capacity to decrease by approximately 7.5% in 2009 compared to 2008. As a result, as announced in June 2009, AMR expects second half 2009 mainline domestic capacity to decline by approximately 7.5% and international capacity to decline by approximately 5.5% compared to the second half of 2008... The co estimates that the impact of the H1N1 virus reduced second quarter revenue by approximately $50 million to $80 million... AMR's Net Debt, which it defines as Total Debt less unrestricted cash and short-term investments, was $11.4 billion at the end of the second quarter of 2009, compared to $10.1 billion at the end of the second quarter of 2008.

9:06AM On the Wires : China Housing & Land Development (CHLN) announces that it has entered a Letter of Intent to acquire an 11-acre tract of land in the center of Xi'an, China. The company intends to develop a large mid-upper income residential and commercial development project on this site, with gross floor area of 200,000 sq. meters... Baxter International (BAX) and Halozyme Therapeutics (HALO) announce completion of patient enrollment in the Phase III pivotal study of GAMMAGARD LIQUID with rHuPH20 for the treatment of primary immunodeficiency disorder. Patients will receive monthly subcutaneous injections of Halozyme's rHuPH20 with Baxter's GAMMAGARD LIQUID... CME Group (CME) announces the launch of S&P 500 Weekly Options contracts scheduled to begin trading August 24. These contracts are listed with, and subject to, the rules and regulations of the Chicago Mercantile Exchange.

9:03AM MAG Silver options San Ramone Property, Zacatecas (MVG) 4.91 : Co reports that it has executed an option agreement to acquire 100% interest subject to a 1.5% Net Smelter Royalty in the San Ramone property in Zacatecas State, Mexico. The San Ramone property combined with MAG's existing adjoining holdings at Lagartos SE, gives MAG control of a significant portion of the eastern part of the historic Mala Noche silver vein system. The Lagartos SE area which has been a major focus of MAG's exploration efforts in the region is located 93 kilometres south of the Fresnillo District and the site of the Valdecanas vein discovery. Under the four year agreement MAG may acquire a 100 per cent interest, from Castle Resources in the property subject to certain cash payments and work commitments. The basic terms of the option agreement commit MAG Silver to expend $500k during the first year and make a $75k payment on signing of the agreement. For subsequent years, at its option, MAG is also required to make work expenditures of $500k during the second year of the option, $1,000,000 during the third year of the option, and $1.25 mln during the fourth year of the option for total work related expenditures of $3.25 mln. In addition, MAG Silver has also agreed to an optional cash payment of $750k on or before the fifth anniversary of the agreement. Castle will retain a 1.5% NSR in the project.

9:03AM Reminder: Industrial Production and Capacity Utilization data due out in about 12 min at 9:15ET (ECONX) :  

9:01AM OXiGENE to raise ~$10 mln in a registered direct offering (OXGN) 1.98 : Co announces that it will raise ~$10 mln in gross proceeds, before deducting placement agent fees and other estimated offering expenses, in a registered direct offering of 6.25 million units, at a price of $1.60 per unit. Each unit will consist of (i) one share of common stock, (ii) a warrant exercisable for five years to purchase 0.45 shares of common stock at an exercise price of $2.10 per share of common stock, and (iii) a warrant.

9:01AM Converted Organics announces that its Gonzales, California manufacturing facility produced and sold 64% more liquid organic fertilizer during the first six months of 2009 than during the same period in 2008 (COIN) 0.99 : Co announces that its Gonzales, California manufacturing facility produced and sold 64 percent more liquid organic fertilizer during the first six months of 2009 than during the same period in 2008. A total of 839,000 gallons were manufactured and shipped between January and June of this year, compared to 510,000 gallons during the first half of last year.

8:53AM Rowan Cos announces proposed senior notes offering of $375 mln, maturing 2019 (RDC) 18.77 :  

8:46AM Texas Industries misses by $0.06, misses on revs (TXI) 32.01 : Reports Q4 (May) loss of $0.12 per share, excluding non-recurring items, $0.06 worse than the First Call consensus of ($0.06); revenues fell 31.5% year/year to $182.4 mln vs the $193.9 mln consensus. "This year's loss is solely due to the goodwill impairment charge, but after adjusting for this non-cash event, our results still reflect the difficult economic environment in which we operate. While things are challenging, our people are doing a great job of not accepting the status quo and they are changing the way we operate by quickly adjusting to market conditions. I am also pleased to have more than 80% of our sales occur in Texas. I believe the Texas market is one of the strongest and is well positioned to grow once the recovery begins."

8:42AM Worthington misses by $0.05, misses on revs (WOR) 12.02 : Reports Q4 (May) loss of $0.02 per share, excluding non-recurring items, $0.05 worse than the First Call consensus of $0.03; revenues fell 45.7% year/year to $471.6 mln vs the $477.4 mln consensus. Co says the last nine months of the fiscal year were very difficult as the global economy plunged into deep recession. Pressure Cylinders and its WAVE joint venture have continued to produce good earnings during the recession. While not immune, both have performed well. Sales for many of Cylinders' product lines continue to gain share. In Steel Processing, volume contraction appears to be at or near bottom. Metal Framing is likely to face continued declines in its market, but the co remains focused on keeping this business cash neutral in the coming year.

8:35AM On the Wires : MicroStrategy (MSTR) announces that LinkedIn has selected MicroStrategy for reporting and analytics... Schering-Plough (SGP) announces that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

8:31AM Scientific Games awarded contract with Ladbrokes (SGMS) 15.62 : Co announces its wholly owned subsidiary, The Global Draw, has been awarded a three year contract to supply multi-game server based gaming terminals to 78 Ladbrokes betting shops in the United Kingdom, which will house approximately 302 terminals.

8:31AM Columbia Labs announces that Lawrence Gyenes is appointed Chief Financial Officer effective immediately (CBRX) 1.15 :  

8:30AM Campbell Soup reaffirms FY09 guidance, says adjusted EPS growth to exceed 5-7% range (CPB) 29.39 : Guidance equates to exceeding a range of $2.19-2.24, consensus is $2.17. The company expects its fiscal 2009 sales, EBIT and EPS growth rates to be negatively impacted by approximately 5 percentage points as a result of currency translation.

8:30AM NIV IntelliMedia Tech Grp wins new $20 million notebook contract (NIV) 2.35 : Co announces it has won a contract worth approximately US$20 mln to supply OEM notebooks to a Hong Kong-based distributor. Under the terms of the contract, NIVS will manufacture and assemble 30,000 notebook units for the Distributor from now until the end of 2009. The Distributor will then sell the OEM notebooks to end customers in overseas markets. The contract will be reviewed at the end of the year.

8:19AM Moody's downgrades state of California to Baa1 from A2; rating remains on watchlist for possible downgrade : Moody's Investors Service has downgraded the State of California's general obligation rating to Baa1 from A2. The state's lease debt and other state-backed debt have also been downgraded. The ratings remain on Watchlist for possible downgrade. The downgrade reflects the increased risk to the legally or constitutionally required payments ("priority payments") as the state deadlock continues and the controller has begun to make certain payments that are not legally or constitutionally required to be paid on time ("non-priority payments") with IOUs. Moody's believes that as the days and weeks go by without enacted solutions to the current cash crisis and the $26 billion budget gap, the risk to priority payments, and eventually debt service payments, is increasing. The downgrade incorporates the risk we believe exists at the current time, as well as the state's inability to solve the current difficulties in a timely fashion. Bonds that are secured by non-priority payments (such as those issued by the state's regional centers or any others around which the payment status is unclear-such as those secured by judgments) may have increased downward pressure on the ratings in the near future if no action is taken by the state to solve the cash crisis and non-priority payments continue to be paid with IOUs.

8:16AM Reminder: CPI and Empire Manufacturing data due out in about 14 min at 8:30ET (ECONX) :  

8:14AM Gannett beats by $0.10, misses on revs (GCI) 3.49 : Reports Q2 (Jun) earnings of $0.46 per share, excluding non-recurring items, $0.10 better than the First Call consensus of $0.36; revenues fell 17.8% year/year to $1.41 bln vs the $1.46 bln consensus. Co said,  "We continue to position the company for the eventual rebound in the economy and the evolving media landscape as we navigate through this unprecedented economic storm. The economic headwinds, which continued to constrain advertising demand, masked several important achievements in the quarter. In our digital segment, pro forma operating profits rose almost 84 percent. Total digital revenues across all of our segments were over $225 million. Retransmission revenues in our Broadcasting segment rose three-fold partially offsetting weak auto advertising demand and lower political spending. In our publishing segment, while advertising revenue comparisons remain difficult, second quarter year-over- year comparisons improved versus first quarter comparisons and June was our best comparison month thus far this year".

8:06AM On the Wires : Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, has filed an Abbreviated New Drug Application with the FDA... CSC (CSC) announces that it has signed a new information technology outsourcing services renewal contract with Henry Ford Health System. The new five-year, three-month agreement runs through March 2014 and has an estimated total contract value of $115 mln. The agreement was signed during the third quarter of CSC's fiscal year 2009... MTM Technologies (MTMC) announced that it has submitted written notice to the NASDAQ Stock Market of its intention to delist its common stock from NASDAQ and to file a Form 25 with the Securities and Exchange Commission and NASDAQ to effect the delisting.

8:02AM Cardium Therapeutics's InnerCool Therapies business to be acquired by Royal Philips Electronics (CXM) 1.94 : The co announces that it has entered into a definitive Asset Purchase Agreement for the acquisition of Cardium's InnerCool Therapies business by Royal Philips Electronics (PHG). The asset purchase transaction for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables, is subject to customary closing conditions but is expected to close shortly. Once this transaction is complete the InnerCool business will operate within Philips' Healthcare sector.

8:02AM China Information Security Technology announces $26.28 mln in newly signed contracts in 2Q09 (CPBY) 2.92 : Co announces that its newly signed contracts in the second quarter of 2009 were valued at approximately US$26.28 million, an increase of over 42% compared to the contracts signed during first quarter 2009.

8:01AM Bemis raises Q2 & FY09 EPS guidance above consensus (BMS) 25.13 : Co raises guidance for Q2 (Jun), sees EPS of approx $0.47 vs. $0.41 First Call consensus, prior guidance $0.35-0.43. Co raises guidance for FY09 (Dec), sees EPS of $1.68-1.75 vs. $1.59 consensus, prior guidance $1.50-1.70. Results for the second quarter of 2009 benefited from lower raw material costs related to second quarter shipments, as well as the positive impact of cost management initiatives implemented during the fourth quarter of 2008 and the first quarter of 2009.

7:55AM WW Grainger beats by $0.07, reports revs in-line (GWW) 82.58 : Reports Q2 (Jun) earnings of $1.21 per share, $0.07 better than the First Call consensus of $1.14; revenues fell 12.7% year/year to $1.53 bln vs the $1.52 bln consensus. Co said, "We have not seen an indication of an economic turnaround at this point but our results indicate that we are gaining market share during this recession. We are in a great position to grow when the economy eventually recovers. We're expanding our sales force to improve customer coverage. Also during the quarter, we announced two ways we'll expand our geographic coverage outside of North America by making small, additional investments in India and in Japan."

7:54AM Abbott Labs reports EPS in-line, revs in-line; guides Q3 EPS in-line; reaffirms FY09 EPS guidance (ABT) 46.49 : Reports Q2 (Jun) earnings of $0.89 per share, excluding non-recurring items, in-line with the First Call consensus of $0.89; revenues rose 2.5% year/year to $7.5 bln vs the $7.55 bln consensus. Co issues in-line guidance for Q3, sees EPS of $0.88-0.90, excluding non-recurring items, vs. $0.90 consensus. Co reaffirms guidance for FY09, sees EPS of $3.65-3.70, excluding non-recurring items, vs. $3.69 consensus.

7:44AM On The Wires : NetLogic Microsystems (NETL) and Taiwan Semiconductor Manufacturing (TSM) announced their collaboration on the industry-leading 40nm-G semiconductor process technology for NetLogic Microsystems' next-generation advanced knowledge-based processors and 10/40/100 Gigabit Ethernet physical layer solutions... Perot Systems Corporation (PER) announced that it has entered an agreement with Zoomlion Heavy Industry Science and Technology Development to explore utilization of technology and engineering services to give both companies an increased presence in the construction equipment industry in China... Silver Wheaton (SLW) announced that as reported by Goldcorp (GG), construction of the first sulphide process line at Goldcorp's world-class gold-silver-lead-zinc Penasquito mine in Zacatecas, Mexico is now complete and commissioning work is advancing on schedule. Production and shipment of first concentrates are still targeted for the second half of 2009... Elbit Systems (ESLT) announced that it was awarded a contract from the Israeli Ministry of Defence for the establishment of a mission planning center for the Israeli Air Force's pilots of F-16C/D and F-16I fighter aircraft. The project is valued at approximately $55 million, subject to necessary approvals during the project... Acacia Research Corporation (ACTG) announced today that its Financial Systems Innovation subsidiary has entered into a settlement agreement covering a patent that applies to credit card fraud protection technology with The Finish Line (FINL). This resolves a dispute that was pending before the United States District Court for the Northern District of Georgia concerning The Finish Line.

7:35AM On the Wires : MiddleBrook Pharmaceuticals (MBRK) announced that it has implemented a $20 maximum copay program for MOXATAG tablets, 775 mg...Oncolytics Biotech (ONCY) announced that a poster presentation entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the American Society for Virology.

7:31AM Alliance Data provides private label performance update for June 2009 (ADS) 37.80 : Co announces an update on its Private Label Credit segment. The co notes that the Master Trust data represents a subset of the Company's total managed portfolio. The co announces that for the month ended June 30, 2009 the YoY portfolio growth grew by 10%, while the net charge-offs as a percentage of average managed receivables grew by 9.6%. For the three months ended June 30, 2009 YoY portfolio growth grew by 10%, while the net charge-offs as a percentage of average managed receivables grew by 9.8% and for the six month ended June 30, 2009 YoY portfolio growth grew by 10%, while the net charge-offs as a percentage of average managed receivables grew by 9.3%.

7:30AM KVH Industries announces a new $2.5 mln order, expanding role of KVH Fiber Optic Gyros in remote weapon stations (KVHI) 6.98 :  

7:30AM Hersha Hospitality Trust announces sale of non-core properties (HT) 2.29 : Co announced the sale of three properties. The properties include a Mainstay Suites and a Comfort Inn in Frederick, MD and a Four Points in Revere, MA. Hersha is selling the Frederick properties, with a total of 145 rooms, for $10.3 million. The 180-room Four Points Reserve is a joint-venture in which the Company is selling its 55% interest for $2.5 million. Net proceeds from the sales are expected to total $7.1 million, and the Company will record a net gain of approximately $1.2 million in the third quarter of 2009.

7:10AM On the Wires : Spectranetics (SPNC) reported the first human procedures using its Turbo-Tandem System, which had earlier received FDA clearance and CE mark approval for marketing in the US and the EU... Alnylam Pharmaceuticals (ALNY) announced that the European Patent Office has upheld its "Kreutzer-Limmer II" '061 patent in oral proceedings held before the European Opposition Board... Goodrich Petroleum (GDP) announced results on four additional Haynesville Shale wells.

7:07AM Medtox Scientific misses single analyst estimate on top and bottom line (MTOX) 8.98 : Reports Q2 (Jun) earnings of $0.04 per share, $0.06 worse than the single estimate of $0.10; revenues fell 2.7% year/year to $21.3 mln vs the $21.7 mln single est.

7:05AM Targacept TC-5214 achieves all primary and secondary outcome measures in Phase 2b Trial as augmentation treatment for major depressive disorder (TRGT) 3.06 : Co announces positive top-line results from a double blind, placebo controlled, flexible dose Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment for major depressive disorder, or M.D.D, in subjects who did not respond adequately to first-line treatment with citalopram alone. The result on the primary outcome measure for the trial, mean change between treatment and placebo (placebo + citalopram) from baseline on the Hamilton Rating Scale for Depression-17, or HAM-D, was highly statistically significant in favor of TC-5214 on an intent to treat basis. The results on all of the trial's secondary efficacy measures, including assessments of depression, irritability, disability, cognition, severity of illness and global improvement, were also highly statistically significant in favor of TC-5214 on an intent to treat basis. TC-5214 exhibited a favorable tolerability profile in the trial. The most frequent adverse events were headache, dizziness and constipation. There was no clinically significant difference between the dose groups in discontinuations due to adverse events. There was one serious adverse event in the trial considered by the investigators to be related to study drug (citalopram and/or TC-5214), a seizure experienced by a study subject. TRGT plans to present detailed results from the Phase 2b trial of TC-5214 at the Society for Neuroscience meeting scheduled for Oct 2009. TRGT is active in discussions with multiple pharmaceutical companies with the goal of identifying a strategic partner to assist in the global development and planned commercialization of TC-5214. TRGT expects Phase 3 clinical development to be initiated in the second quarter of 2010, following planned discussions with FDA and production of clinical trial material.

7:03AM Silvercorp Metals updates market regarding its offer to acquire all the outstanding shares of Klondex (SVM) 2.98 : Co announces that its offer entitles Klondex's shareholders to receive 0.50 shares of Silvercorp for each outstanding Klondex share validly tendered to the offer and not withdrawn, representing a premium of approximately 59% over Klondex's closing share price on the TSX on June 5, 2009, the last trading day prior to Silvercorp's announcement of its intention to make the offer. The offer represents a premium of approximately 63% over Klondex's volume-weighted average price on the TSX for the 20 trading days ended June 5, 2009. So long as the Klondex shareholder rights plan remains in place, Silvercorp will not take up any shares tendered to its offer. Silvercorp intends to petition the British Columbia Securities Commission during the week of July 13, 2009 to cease trade the rights issued under the Klondex shareholder rights plan.

7:02AM Cadence Pharmaceuticals announces priority review and acceptance of NDA submission for Acetavance for treatment of acute pain and fever (CADX) 10.44 10.44 : Co announces that its New Drug Application (NDA) for Acetavance, its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and designated for Priority Review. Priority Review is granted to those products that address significant unmet medical needs or have the potential to provide a significant improvement compared to marketed products and provides for a review period of six months from the date of NDA submission. The Priority Review designation reduces the target review period for the NDA from ten months to six months. Acceptance of the NDA submission indicates that the FDA has made a threshold determination that the NDA is sufficiently complete to permit a substantive review. Co says, "We are very pleased with the FDA's decision to grant the Acetavance NDA a Priority Review, which we believe reflects the potential of Acetavance to fulfill a significant unmet need for a new class of intravenous medication to treat acute pain and fever in adults and children, for which there remains a large gap in the U.S. treatment paradigm."

7:01AM LaBarge awarded $12 million in contracts from Kaman Aerospace for Black Hawk helicopter program (LB) 8.88 : Co announces it has been awarded contracts valued at approximately $12 mln from Kaman Aerospace Corporation to provide cockpit wiring harnesses for several models of the Black Hawk helicopter. The Company anticipates additional follow-on orders. Kaman is a subcontractor to Sikorsky Aircraft, a subsidiary of United Technologies (UTX), on the Black Hawk helicopter program.

7:00AM Fuel-Tech announces receipt of a commercial FUEL CHEM order from an existing domestic electric utility customer (FTEK) 8.22 :  

6:37AM Wolverine reports EPS in-line, beats on revs; raises FY09 EPS, still in-line, guides FY09 revs (WWW) 22.01 : Reports Q2 (Jun) earnings of $0.27 per share, in-line with the First Call consensus of $0.27; revenues fell 7.9% year/year to $246.4 mln vs the $242.8 mln consensus. Co rasies guidance for FY09, still inline, sees EPS of $1.55-1.73, excluding non-recurring items, vs. $1.66 consensus, up from previous guidance of $1.50-1.70; sees FY09 revs of $1.07-1.12 bln vs. $1.12 bln consensus. Co says, "We are pleased with our second quarter results, which were driven by our ability to grow proven brands and extend the global reach of new brands. During the quarter, we achieved a double-digit increase in our Merrell business in the U.S. and got off to a strong start with the Chaco brand. Company revenue was above our internal plan for the quarter, which helped contribute to solid earnings results. Harley-Davidson and Sebago each posted revenue increases in the quarter, as did Hush Puppies in the important Canadian market. These positive results underscore the strength of our multi-brand, multi-country business model and our ability to execute during challenging economic times. We are very pleased that our strong year-to-date performance provides us with the confidence to raise earnings guidance in this challenging environment. We remain encouraged by consumer demand for our lifestyle brands and are pleased with the retail and consumer response to our newest brands, Cushe and Chaco. Our continuing focus on product innovation is helping us outperform in these difficult global economic conditions."

6:26AM S&P futures vs fair value: +14.70. Nasdaq futures vs fair value: +27.5. :  

6:26AM European Markets : FTSE...4301.84...+64.20...+1.50%. DAX...4871.81...+90.10...+1.90%.

6:26AM Asian Markets : Nikkei...9269.25...+7.40...+0.10%. Hang Seng...18258.66...+372.90...+2.10%.

6:23AM Fifth Street Finance announces proposed public offering of 6.5 mln common shares (FSC) 9.88 :  

6:08AM On The Wires : INX (INXI) announces that it has entered into a contract with E-Waste Recovery Services of Northern Calif. for a server recycling program... Ceragon Networks (CRNT) announces that it has signed a multi-year global supply agreement with the Hutchison 3 Group.

6:07AM On The Wires (OPEMX) : INX (INXI) announces that it has entered into a contract with E-Waste Recovery Services of Northern Calif. for a server recycling program... Ceragon Networks (CRNT) announces that it has signed a multi-year global supply agreement with the Hutchison 3 Group.

6:07AM On The Wires (OPEMX) : INX (INXI) announces that it has entered into a contract with E-Waste Recovery Services of Northern Calif. for a server recycling program... Ceragon Networks (CRNT) announces that it has signed a multi-year global supply agreement with the Hutchison 3 Group.

6:07AM On The Wires (OPEMX) : INX (INXI) announces that it has entered into a contract with E-Waste Recovery Services of Northern Calif. for a server recycling program... Ceragon Networks (CRNT) announces that it has signed a multi-year global supply agreement with the Hutchison 3 Group.

6:05AM Susser Holdings provides 2Q09 operating results update (SUSS) 11.49 : Co expects to report same-store merchandise sales growth for the 2Q09 of approx 4.6%. Retail average per-store fuel volumes are expected to increase by 6.5% year/year. For the first six months of the year, Susser expects to report an increase in same-store merchandise sales of approx 5.2% year/year. Retail average per-store fuel volumes are expected to be 5.5% higher.

6:03AM Lufkin Industries misses by $0.01, misses on revs (LUFK) 40.75 : Reports Q2 (Jun) earnings of $0.40 per share, excluding non-recurring items, $0.01 worse than the First Call consensus of $0.41; revenues fell 29.1% year/year to $123.7 mln vs the $193.1 mln consensus. CEO J. Glick comments, "Bookings in both our Oil Field and Power Transmission divisions were up from the first quarter of 2009, but they were down significantly from 2008 levels, when we saw record levels of activity. A number of international projects continue to be deferred while some North American projects continue to be cancelled altogether, particularly by the majors. However, cancellations were down significantly from the first quarter of 2009." Co notes lower natural gas prices are impacting cash flows and budgets of co's major and independent oil and gas customers. As a result, crude oil projects are seeing delays or cancellations.

1:21AM CoBiz prices 12.67 mln common share offering at $4.50/share (COBZ) 4.84 :  

1:19AM ADTRAN beats by $0.02, beats on revs (ADTN) 21.74 : Reports Q2 (Jun) earnings of $0.30 per share, includes stock-based compensation, $0.02 better than the First Call consensus of $0.28; revenues fell 7.4% year/year to $121.5 mln vs the $117.9 mln consensus.

1:14AM On The Wires : In a market survey conducted in May 2009 involving 101 endocrinologists and 102 primary care physicians (all based in U.S) and utilizing MannKind's (MNKD) next generation inhaler, physicians expressed a preference for AFRESA for approx 25% of both type 1 and type 2 patients that would qualify for use of AFRESA... Oilsands Quest (BQI) announces it is extending until July 29, 2009 the date by which it must file its Form 10-K for the year ended April 30, 2009 by filing a Form 12b-25 with SEC.

1:11AM ASML Holding reports EPS in-line, beats on revs; guides Q3 revs above consensus (ASML) 22.00 : Reports Q2 (Jun) loss of EUR 0.24 per share, in-line with the First Call consensus of EUR(0.24); revenues fell 67.2% year/year to EUR276.6 mln vs the EUR216 mln consensus. Co issues upside guidance for Q3, sees Q3 revs of EUR450 mln vs. EUR358.77 mln consensus. ASML's order backlog as of June 28, 2009 was EUR 1,064 mln, totaling 43 systems with an average selling price of EUR 24.7 mln. ASML's backlog as of March 29, 2009 was valued at EUR 853 mln, totaling 38 systems with an average selling price of EUR 22.4 mln. 2Q09 gross margin was 12.5%, compared with the 1Q09 gross margin of 6.7%, reflecting an increase in sales from extremely low levels in 1Q09. Co expects gross margin in 3Q09 of approx 30%.